On November 14-16, XXI Russian Oncology Congress passed in Moscow. It is one of the largest international events in the field of oncology, in which more than 5,000 doctors take part annually.

Permanent organizers of the congress:

N.N. Blokhin Russian Cancer Research Center and the Russian Society of Clinical Oncology under the aegis of the Russian Oncology Association.

The following issues discussed in this year:

National Cancer Control Program. How will Russian oncology benefit from it?

Regional problems of oncology

How do we bring together clinical guidelines and standards of care?

Problems of specialists training

What does the Russian pharmaceutical industry expect from the national cancer program?

Russian innovations in drug development and anticancer treatment were presented at the Skolkovo Foundation session on November, 15th.

Results of a multicenter phase II study on the administration of Quisinostat (HDAC1 inhibitor) in combination with Cisplatin and Paclitaxel in women with a platinum-resistant recurrent ovarian cancer were also submitted within the session. The report was presented by Mikhail Y. Fedyanin, Ph.D., oncologist, Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin RSCC.

Quisinostat (a histone deacetylase inhibitor, HDAC) is a new generation drug developed by the Russian pharmaceutical company NewVac (the ChemRar group of companies) in association with Janssen Pharmaceutica (Johnson & Johnson LLC), which is notable for a longer effect and a possibility to administrate it in the tablet form.